Skip to main content

01.12.2015 | Research | Ausgabe 1/2015 Open Access

Radiation Oncology 1/2015

Feasibility of accelerated partial breast irradiation with volumetric-modulated arc therapy in elderly and frail patients

Radiation Oncology > Ausgabe 1/2015
Olivier Riou, Pascal Fenoglietto, Céline Bourgier, Olivier Lauche, Fatiha Boulbair, Marie Charissoux, Angélique Ducteil, Norbert Aillères, Claire Lemanski, David Azria
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

OR, DA, CL and PF conceived the study. OR, FB and OL collected data. OR drafted the manuscript. OR, CL, OL, PF, FB, NA, MC, AD, CB and DA participated in coordination and helped to draft the manuscript. All authors have read and approved the final manuscript.



Accelerated partial breast irradiation (APBI) is an option for adjuvant radiotherapy according to ASTRO and ESTRO recommendations. Among the available techniques, volumetric-modulated arc therapy (VMAT) is attractive but has not been extensively studied for APBI. This study assessed its feasibility, tolerance and early oncological outcomes.


We analysed the data of nine patients (median age 74 years) with ten lesions (one bilateral cancer) treated from May 2011 to July 2012 with APBI using VMAT. The radiation oncologist delineated the surgical tumour bed, and added an 18 mm isotropic margin to obtain the planning target volume (PTV). The dose was 40 Gy prescribed in 4 Gy fractions given twice a day over five days. Patients were regularly followed for toxicities and oncological outcomes.


Mean PTV was 100.0 cm3 and 95 % of the PTV received a mean dose of 99.7 % of the prescribed dose. Hot spots represented 0.3 % of the PTV. 6.2 %, 1.6 % and 0.3 % of the ipsilateral lung volume received 5 Gy (V5Gy), 10 Gy (V10Gy) and 20 Gy (V20Gy), respectively. Regarding the contralateral lung, V5Gy was 0.3 %, and V10Gy and V20Gy were nil. V5Gy accounted for 3.1 % of the heart. An average 580 monitor units were delivered. No acute or late grade ≥ 2 toxicities were observed. With a median follow-up of 26 months, no relapses occurred.


In our study, VMAT allowed optimal dosimetry with consequential high therapeutic ratio in elderly and frail patients.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

Radiation Oncology 1/2015 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.